User login
Key clinical point: A 140 mg dose of erenumab monthly was well tolerated and showed sustained efficacy over 2 years in patients with episodic migraine who failed 2-4 prior migraine preventive treatments.
Major finding: At week 112, the proportion of patients achieving ³50%, ³75%, and 100% reduction in monthly migraine days from baseline was 57.2%, 30.6%, and 16.2%, respectively. Overall, 86.3% of patients experienced treatment-emergent adverse events, the most common being nasopharyngitis, influenza, and back pain. No deaths or new safety signals were reported.
Study details: Findings are 2-year follow-up results of the phase 3b LIBERTY study including 240 patients with episodic migraine who failed 2-4 prior prophylactic treatments, completed placebo-controlled double-blind treatment phase, and were enrolled in the 3-year open-label extension phase with 140 mg erenumab monthly.
Disclosures: This study was supported by Novartis Pharma, Switzerland. Some investigators reported receiving grants and fees from, owning stocks in, or being an employee of various pharmaceutical companies, including Novartis.
Source: Ferrari MD et al. J Neurol Neurosurg Psychiatry. 2021 (Nov 29). Doi: 10.1136/jnnp-2021-327480.
Key clinical point: A 140 mg dose of erenumab monthly was well tolerated and showed sustained efficacy over 2 years in patients with episodic migraine who failed 2-4 prior migraine preventive treatments.
Major finding: At week 112, the proportion of patients achieving ³50%, ³75%, and 100% reduction in monthly migraine days from baseline was 57.2%, 30.6%, and 16.2%, respectively. Overall, 86.3% of patients experienced treatment-emergent adverse events, the most common being nasopharyngitis, influenza, and back pain. No deaths or new safety signals were reported.
Study details: Findings are 2-year follow-up results of the phase 3b LIBERTY study including 240 patients with episodic migraine who failed 2-4 prior prophylactic treatments, completed placebo-controlled double-blind treatment phase, and were enrolled in the 3-year open-label extension phase with 140 mg erenumab monthly.
Disclosures: This study was supported by Novartis Pharma, Switzerland. Some investigators reported receiving grants and fees from, owning stocks in, or being an employee of various pharmaceutical companies, including Novartis.
Source: Ferrari MD et al. J Neurol Neurosurg Psychiatry. 2021 (Nov 29). Doi: 10.1136/jnnp-2021-327480.
Key clinical point: A 140 mg dose of erenumab monthly was well tolerated and showed sustained efficacy over 2 years in patients with episodic migraine who failed 2-4 prior migraine preventive treatments.
Major finding: At week 112, the proportion of patients achieving ³50%, ³75%, and 100% reduction in monthly migraine days from baseline was 57.2%, 30.6%, and 16.2%, respectively. Overall, 86.3% of patients experienced treatment-emergent adverse events, the most common being nasopharyngitis, influenza, and back pain. No deaths or new safety signals were reported.
Study details: Findings are 2-year follow-up results of the phase 3b LIBERTY study including 240 patients with episodic migraine who failed 2-4 prior prophylactic treatments, completed placebo-controlled double-blind treatment phase, and were enrolled in the 3-year open-label extension phase with 140 mg erenumab monthly.
Disclosures: This study was supported by Novartis Pharma, Switzerland. Some investigators reported receiving grants and fees from, owning stocks in, or being an employee of various pharmaceutical companies, including Novartis.
Source: Ferrari MD et al. J Neurol Neurosurg Psychiatry. 2021 (Nov 29). Doi: 10.1136/jnnp-2021-327480.